Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles

Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles

Adaptive immune resistance in cancer describes the various mechanisms by which tumors adapt to evade anti-tumor immune responses. IFN-γ induction of programmed death-ligand 1 (PD-L1) was the first defined and validated adaptive immune resistance mechanism. The endoplasmic reticulum (ER) is central t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Paola A. Castagnino, Derick A. Haas, Luca Musante, Nathalia A. Tancler, Bach V. Tran, Rhonda Kean, Alexandra R. Steck, Luis A. Martinez, Elahe A. Mostaghel, D. Craig Hooper, Felix J. Kim
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Series:	Cancer Biology & Therapy
Subjects:	Sigma1/SIGMAR1 extracellular vesicle (EV) programmed death ligand 1 (PD-L1) EV-associated PD-L1 (evPD-L1) Interferon-gamma (ifn-γ) adaptive immune resistance (AIR)
Online Access:	https://www.tandfonline.com/doi/10.1080/15384047.2025.2455722
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Increased serum soluble PD-l1 levels in patients with advanced stages of chronic kidney disease
by: Ayaka Hayashi, et al.
Published: (2025-01-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer
by: Vesna Ćeriman Krstić, et al.
Published: (2025-01-01)

Developing a risk score using liquid biopsy biomarkers for selecting Immunotherapy responders and stratifying disease progression risk in metastatic melanoma patients
by: Amalia Azzariti, et al.
Published: (2025-02-01)

Discovery of novel biphenyl compounds bearing hydroxamic acid moiety as the first PD-L1/class I HDACs dual inhibitors
by: Dandan Yuan, et al.
Published: (2025-12-01)

Extraction, GC-MS analysis, cytotoxic, anti-inflammatory and anticancer potential of Cannabis sativa female flower; in vitro, in vivo and in silico
by: Waqas Safir, et al.
Published: (2025-02-01)

Inosine enhances the efficacy of immune‐checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study
by: Haiqing Zhao, et al.
Published: (2024-09-01)

Infiltration of CD8+ cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma
by: Mengdi Fu, et al.
Published: (2025-02-01)

Germline Human Leukocyte Antigen Status is Associated With Immunotherapy-Induced Pneumonitis and Treatment Response in Patients With Non–Small Cell Lung Cancer With High Programmed Death-Ligand 1 Expression
by: Alvin H.K. Cheung, MBBS, PhD, et al.
Published: (2025-01-01)

Formin protein DAAM1 positively regulates PD-L1 expression via mediating the JAK1/STAT1 axis in pancreatic cancer
by: Rui Xu, et al.
Published: (2025-01-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

ArfGAP with the SH3 Domain, Ankyrin Repeat and PH Domain 1 Inversely Regulates Programmed Death-Ligand 1 Through Negative Feedback of Phosphorylated Epithelial Growth Factor Receptor and Activation of Nuclear Factor-Kappa B in Non-Small Cell Lung Cancer
by: Chiba N, et al.
Published: (2025-01-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
by: Yanan Zhao, et al.
Published: (2024-08-01)

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
by: Cecilia Olsson Ladjevardi, et al.
Published: (2024-11-01)

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy
by: Myrna Luna-Gutiérrez, et al.
Published: (2025-01-01)

Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile
by: Manuel Weber, et al.
Published: (2019-03-01)

ErbB- and MUC1-targeted CAR-T cell immunotherapy of oral squamous cell carcinoma
by: Saffron E. Summers, et al.
Published: (2023-03-01)

Prognostic and clinicopathological role of soluble programmed cell death ligand-1 in patients with diffuse large B-cell lymphoma: a meta-analysis
by: Hongbin Lu, et al.
Published: (2025-01-01)

A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report
by: Jingjing Chai, et al.
Published: (2025-02-01)

NUAK1 acts as a novel regulator of PD-L1 via activating GSK-3β/β-catenin pathway in hepatocellular carcinoma
by: Chao-Yan Yao, et al.
Published: (2025-02-01)

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)

Disulfidptosis as a key regulator of glioblastoma progression and immune cell impairment
by: Yifu Shu, et al.
Published: (2025-01-01)

PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer
by: Jiacheng Li, et al.
Published: (2025-01-01)

Prognostic implications of immune classification based on PD-L1 expression and tumor-infiltrating lymphocytes in endocervical adenocarcinoma
by: Li-Jun Wei, et al.
Published: (2025-02-01)

Genome-wide transcriptome analysis and drug target discovery reveal key genes and pathways in thyroid cancer metastasis
by: Minjing Zou, et al.
Published: (2025-02-01)

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients
by: Ting Yan, et al.
Published: (2025-01-01)

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01)

Colorimetric aptasensor coupled with a deep-learning-powered smartphone app for programmed death ligand-1 expressing extracellular vesicles
by: Adeel Khan, et al.
Published: (2025-01-01)

Enhanced effect of radiofrequency ablation on HCC by siRNA-PD-L1-endostatin Co-expression plasmid delivered
by: Pengfei Chen, et al.
Published: (2025-03-01)

A Smart Nanomedicine Unleashes a Dual Assault of Glucose Starvation and Cuproptosis to Supercharge αPD‐L1 Therapy
by: Yiming Xu, et al.
Published: (2025-01-01)

Platinum drugs upregulate CXCR4 and PD‐L1 expression via ROS‐dependent pathways, with implications for novel combined treatment in gastric cancer
by: Xiaoyu Kang, et al.
Published: (2025-01-01)

DRG2 as a Biomarker to Enhance the Predictive Efficacy of PD-L1 Immunohistochemistry Assays
by: Muralidharan Mani, et al.
Published: (2024-12-01)

Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis
by: Preston Ngo, et al.
Published: (2025-02-01)

Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1
by: Coco Duizer, et al.
Published: (2025-12-01)

Caerin 1.1/1.9-mediated antitumor immunity depends on IFNAR-Stat1 signalling of tumour infiltrating macrophage by autocrine IFNα and is enhanced by CD47 blockade
by: Junjie Li, et al.
Published: (2025-01-01)

Case report: A case of type 1 diabetes with diabetic ketoacidosis induced by envafolimab treatment in hepatocellular carcinoma
by: Youjia Li, et al.
Published: (2025-01-01)

Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion
by: Yang Xia, et al.
Published: (2025-01-01)